AWM
NBIX icon

Apollon Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Apollon Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Buy
+2,568
New +$381K 0.01% 1087
2023
Q1 		– Sell
-1,734
Closed -$207K – 902
2022
Q4 		$207K Buy
+1,734
New +$203K 0.01% 776

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Apollon Wealth Management's NBIX Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,568 shares worth $433K. The stake represents 0.01% of the portfolio and ranks #1087 among its holdings. This is a return to the name: Apollon Wealth Management previously reported a position in NBIX as recently as Q4 2022.

Apollon Wealth Management first reported a position in NBIX in Q4 2022 and has held it in 2 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Apollon Wealth Management held 2,568 shares of Neurocrine Biosciences worth $433K as of Q2 2026.
  • Neurocrine Biosciences was a new Apollon Wealth Management position in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1087 holding.
  • Apollon Wealth Management first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 2 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.